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Abstract
Aims/hypothesis Pancreatic beta cells play a central role in the
control of glucose homeostasis by secreting insulin to stimu-
late glucose uptake by peripheral tissues. Understanding the
molecular mechanisms that control beta cell function and
plasticity has critical implications for the pathophysiology
and therapy of major forms of diabetes. Selective gene inac-
tivation in pancreatic beta cells, using the Cre-lox system, is a
powerful approach to assess the role of particular genes in beta
cells and their impact on whole body glucose homeostasis.
Several Cre recombinase (Cre) deleter mice have been
established to allow inactivation of genes in beta cells, but
many show non-specific recombination in other cell types,
often in the brain.
Methods We describe the generation of Ins1Cre and
Ins1CreERT2 mice in which the Cre or Cre-oestrogen receptor
fusion protein (CreERT2) recombinases have been introduced
at the initiation codon of the Ins1 gene.
Results We show that Ins1Cre mice induce efficient and selec-
tive recombination of floxed genes in beta cells from the time
of birth, with no recombination in the central nervous system.
These mice have normal body weight and glucose homeosta-
sis. Furthermore, we show that tamoxifen treatment of adult
Ins1CreERT2 mice crossed with Rosa26-tdTomatomice induces
efficient recombination in beta cells.
Conclusions/interpretation These two strains of deleter mice
are useful new resources to investigate the molecular physiol-
ogy of pancreatic beta cells.
Keywords Beta cells . Cre recombinase . Glucose
homeostasis . Hypothalamus . Insulin . Pancreatic islets .
Transgenic mice
Abbreviations
Cre Cre recombinase
CreERT2 Cre-oestrogen receptor fusion protein
eYFP Enhanced yellow fluorescent protein
Flp Flippase
GFP Green fluorescent protein
Neo Neomycin
RIP Rat insulin promoter
Introduction
Pancreatic beta cells participate in glucose homeostasis by
secreting insulin in response to rises in glycaemia to stimulate
glucose uptake by peripheral tissues. To maintain this capacity
over a lifetime, the insulin secretion capacity of individual
beta cells as well as their number may be modulated to
compensate for the development of insulin resistance in target
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tissues. Failure of this beta cell adaptive capacity is a major
cause of the development of diabetic hyperglycaemia. On the
other hand, the enhancement of natural mechanisms of beta
cell adaptation might prove useful for regenerative therapies
in autoimmune type 1 diabetes. Understanding the molecular
basis of beta cell plasticity is therefore a central focus in
diabetes research [1].
Genetically modified mice are being used extensively to
study the role of specific genes in diabetes pathophysiology
[2–5], and several genetic systems have been developed to
overexpress or inactivate genes selectively in beta cells
[6–12]. In particular, recent recombinant technologies have
provided the possibility to selectively inactivate genes of inter-
est in a tissue- and time-dependent manner, as critically
reviewed recently [13]. A particularly useful approach consists
in flanking the DNA sequence to be deleted by tandemly
oriented 34 nucleotide-long lox sequences, which are
recognised by Cre recombinase (Cre), a recombination enzyme
that leads to the elimination of the sequence present between
the two lox sites. Modification of the target DNA sequence with
lox sites is performed by homologous recombination in embry-
onic stem cells, and the mice that are ultimately generated are
crossed with mice that express Cre under a tissue-specific
promoter to allow tissue-specific gene deletion. The use of
Cre-oestrogen receptor fusion protein (CreERT2) [14], which
is Cre fused to a modified form of the ligand-binding domain of
the human oestrogen receptor that can be activated by tamox-
ifen, allows precise time-controlled genetic recombination.
One key aspect of the Cre-lox system is that transgenic
expression of the Cre gene must be specific to the desired
target tissue. Deletion in beta cells has been performed using
mice expressing Cre under the control of various promoters
such as that of the rat Ins2 gene [12, 15], the mouse Ins1
promoter [16] or the human insulin promoter [17]. In contrast
to the mouse Ins2 gene, which is also expressed in the embry-
onic and adult brain, the Ins1 gene is selectively expressed by
the beta cells [18, 19], thereby providing a potential specificity
advantage to drive Cre reporter expression only in beta cells.
Existing transgenics that use insulin gene regulatory regions
typically allow for beta cell gene inactivation; however, they
often also lead to expression in brain regions, mostly the
hypothalamus for the Ins2 promoter, leading to phenotypes
that are complicated by the non-specific site of expression of
the recombinase. Other approaches have used the promoters
of transcription factor genes expressed at different stages of
beta cell development, such as Pdx-1,Neurog3,Nkx2.2, Pax4,
Pax6 or Isl-1 (for detailed review of these lines, see [13]).
Although all of these lead to Cre expression in beta cells, they
also lead to gene deletion either in islet non-beta cells or
diverse non-pancreatic cellular lineages, including widely
used Pdx1-Cre mouse lines that induce recombination in the
exocrine pancreas. There is thus a need for more selective Cre
lines for gene inactivation in beta cells.
The design of a mouse model that transcribes Cre exclu-
sively in beta cells faces several obstacles. One is that gene
regulatory sequences are not exclusively encoded in the 5′
regions of genes but are often determined or modulated by
long-range cis-regulatory interactions, most of which have not
been annotated. This obstacle is best addressed by inserting
the recombinase in the endogenous genomic locus of interest,
rather than using predefined promoter fragments. Another
complexity is that most genes that are enriched in beta cells
are also expressed in other cell types, some of which are
central to glucose homeostasis. Notably, of the two non-
allelic mouse insulin genes, Ins2 is the most abundantly
expressed in beta cells, yet it is also expressed in hypothala-
mus and brain [18]. Thus, even genetic models that succeed in
recapitulating Ins2 expression will unavoidably lead to ex-
pression outside the beta cells, while recapitulation of Ins1
expression is expected to lead to selective beta cell expression
Here, we generated mice in which Cre was introduced at
the initiator codon of the Ins1 locus by homologous recombi-
nation technology so as to ensure faithful expression of the
recombinase in beta cells.We show that this approach allowed
for highly efficient expression of Cre or CreERT2
recombinase in beta cells and that the specificity of expression
was guaranteed with no expression in hypothalamus or other
brain areas and with recombination as early as the time of
birth.
Methods
Mice Ins1Cr e ( Ins1 tm1 ( c r e ) Tho r ) and Ins1Cr eERT2
(Ins1tm1(CreERT2)Thor) knock-in mice were generated by
Genoway (Lyon, France) and kept on a C57Bl/6J genetic
background. Briefly, a targeting vector was created by
inserting the Cre or CreERT2 recombinase genes by homolo-
gous recombination in the second exon of the Ins1 gene so that
the coding region of the recombinase starts at the initiation
codon and replaces the Ins1 coding sequence (Fig. 1). Fol-
lowing transfection of the targeting vector into embryonic
stem cells, negative and positive selections were performed
by diphtheria toxin and neomycin (neo) selection, respective-
ly. Cells with confirmed homologous recombination were
used to generate chimeric mice. These were crossed with
C57Bl/6J mice, and mice with germline transmission were
crossed with C57Bl/6J flippase (Flp) deleter mice to eliminate
the neo cassette. Mice with germline transmission of the
recombined allele and deletion of the neo cassette were then
crossed with Rosa26-eYFP mice [20] or Rosa26-tdTomato
mice [21]. Animals were housed four to five per cage at
23°C on a 12 h light/dark cycle and were fed a standard rodent
chow (Diet 3436; Provimi Kliba, Penthallaz, Switzerland). To
induce recombination in Ins1CreERT2 crossed with Rosa26
reporter mice, tamoxifen (T5648; Sigma-Aldrich, St Louis,
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MO, USA) was dissolved in corn oil at 20 mg/ml, and 2 mg
was injected subcutaneously four times over a 2 week period.
Genotyping Mouse genotyping was performed by PCR anal-
ysis using primers listed in electronic supplementary material
(ESM) Table 1.
Histological and immunodetection procedures For
immunodetection of enhanced yellow fluorescent protein
(eYFP), tdTomato, insulin, glucagon, pancreatic polypeptide
and somatostatin in the pancreas or in the brain, mice
were fixed by perfusion with cold 4% paraformaldehyde
in sodium phosphate buffer (0.1 mol/l, pH 7.4). The
organs were dissected and kept for 4 h in the same
paraformaldehyde solution before overnight incubation
in 30% sucrose, then frozen in isopentane and stored
at −80°C until used.
For immunofluorescence detection studies in eYFP report-
er mice 20 μm cryosections were preincubated for 30 min in a
permeabilisation blocking buffer (0.1 mol/l PBS, pH 7.4, 3%
BSAA8022, 0.3% Triton X-100, 9002-93-1; Sigma-Aldrich),
then incubated overnight at 4°C with a rabbit polyclonal
antibody to green fluorescent protein (GFP) (ab290, diluted
1:2,000; Abcam, Cambridge, UK), a polyclonal guinea pig
anti-insulin (AO564, diluted 1:400; Dako, Baar, Switzerland)
or anti-glucagon (4031-01F, diluted 1:500; Linco Research, St
Charles, MO, USA), a polyclonal anti-pancreatic polypeptide
(diluted 1:1,000; Linco Research) or a polyclonal rabbit anti-
somatostatin (A0566, diluted 1:200; Dako). After washing,
the sections were then incubated for 90 min with Alexa Fluor
488 goat anti-guinea pig IgG (H+L) (A11073, diluted 1:200;
Invitrogen, LuBioScience, Lucerne, Switzerland) or with a
goat anti-rabbit immunoglobulin-Cy3 conjugate (111-165-
144, diluted 1/100; Jackson ImmunoResearch, West Grove,
PA, USA), or for the Rosa26-tdTomatomice with Alexa Fluor
488 goat anti-rabbit IgG (H+L) (A-11008, diluted 1:200;
Invitrogen). Immunofluorescence analysis of tdTomato was
carried out in 3 μm paraffin sections, essentially as described
[22, 23], using a rabbit polyclonal anti-red fluorescent protein
(600-401-379; Rockland Immunochemical, Gilbertsville, PA,
USA).
For enzymatic detection of eYFP, after overnight incuba-
tion with primary antibody, sections were washed and incu-
bated for 90 min with a biotinylated goat anti-rabbit antibody
(BA-1000, diluted 1:750; Vector Laboratories, Burlingame,
CA, USA), incubated for 30 min with a biotin–avidin com-
plex (Vector) and stained using 3,3′-diaminobenzidine tetra-
hydrochloride (Sigma-Aldrich).
Sections were observed using an Axio Imager D1 micro-
scope (Carl Zeiss, Oberkochen, Germany) interfaced with
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Fig. 1 Generation of Ins1Cre and Ins1CreERT2 mice. (a) Structure of the
Ins1 locus, of the targeting vector, of the targeted allele, and of the Ins1Cre
locus following flipase (Flp)-dependent removal of the flipase recognition
site (Frt)-flanked neo cassette. DTA, diphtheria toxin receptor gene; Ex,
exon; ATG, translation initiation codon. (b) The Ins1CreERT2 allele was
obtained using the targeting strategy depicted in (a). (c) Structure of the
Rosa26-eYFP/tdTomato transgene and localisation of the primers
(arrows) used for PCR analysis of the recombined locus. CMV/A, cyto-
megalovirus/actin promoter; (d) PCR analysis shows recombination in
the pancreas but not in the liver, cortex, hypothalamus or cerebellum of
Ins1Cre/+;Rosa26-eYFP. No recombination was observed in the pancreas
of Rosa26-eYFP littermates; amplification of theGapdh gene is used as a
control
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Axiovision software (Carl Zeiss) or a 510 Meta inverted
confocal laser scanning microscope (LSM) with LSM soft-
ware (release 3.5; Zeiss).
Glucose tolerance tests For glucose tolerance tests, 16 h
fasted male and female mice of indicated ages were injected
i.p. with glucose (2 g/kg), and blood glucose levels were
determined from tail–tip bleedings at the indicated times
relative to glucose injections. Blood glucose levels were mea-
sured using a glucometer (Ascensia Breeze 2; Bayer
HealthCare, Switzerland).
Statistical analysis Data are expressed as means±SD or SEM.
Statistical analysis was performed using an unpaired two-
tailed Student’s t test. Values of p<0.05 were considered
significant.
Study approval All breeding and cohort maintenance per-
formed in our animal facility and all experiments were ap-
proved by the Service Vétérinaire du Canton de Vaud and the
Comitè Ètic d’Experimentació Animal of the University of
Barcelona.
Results
Mouse generation Generation of the Ins1Cre and Ins1CreERT2
mice followed the strategy described in Fig. 1a–c and the
Methods section, allowing expression of Cre or CreERT2
from the translation initiation codon of the Ins1 gene. Embry-
onic stem cells with homologous recombination were used to
generate chimeric mice. These were crossed with Flp deleter
mice to remove the neo cassette. The resulting Ins1Cre mice
were crossed with Rosa26-eYFP mice to determine the ana-
tomical sites of Cre-dependent lox site recombination. PCR
analysis of the recombined Rosa26-eYFP locus (Fig. 1c) in-
dicated recombination in whole pancreas DNA preparations
but not in DNA extracted from liver, hypothalamus, cortex or
cerebellum (Fig. 1d).
Assessment of the cellular sites of Cre-induced eYFP ex-
pression was then performed by histological analysis. In the
pancreas, eYFP expression was only observed in islets as
revealed by the endogenous fluorescence of eYFP or by
immunofluorescence detection using anti-GFP antibodies
(Fig. 2a, b). No eYFP expression was observed in the liver
of the same mice (Fig. 2c, d), nor in the pancreas of control
Rosa26-eYFPmice (Fig. 2e, f). Co-staining of the pancreas of
Ins1Cre/+;Rosa26-eYFP mice with islet hormones (insulin,
glucagon, somatostatin or pancreatic polypeptide) showed
that eYFP expression was specific to beta cells within pancre-
atic islets (Fig. 3a–d). We quantified the recombination effi-
ciency in pancreatic cell subtypes using Ins1Cre/+;Rosa26-
tdTomato mice and found that 97.8±1.2% of insulin-
expressing cells showed expression of tdTomato, in contrast
with 3.0±0.3% of glucagon-expressing cells, 0.0% of
somatostatin-expressing cells and <0.01% of CPA-1-
expressing pancreatic acinar cells.
To determine whether recombination could already be seen
at the time of birth, pancreas sections were prepared from
newborn Ins1Cre/+;Rosa26-tdTomato mice and co-stained for
insulin and glucagon. Figure 4a, b shows that expression of
tdTomato was already present in beta cells at birth and no
expression was detected in glucagon-producing alpha cells.
Because Cre mice previously generated to target the pan-
creatic beta cells often showed expression of the transgene in
the brain, in particular in the hypothalamus, we verified ex-
pression of eYFP in different parts of the brain. PCR analysis
(Fig. 1d) showed no detectable recombination of the Rosa26
locus in Ins1Cre/+;Rosa26-eYFP mice in the hypothalamus,
cortex or cerebellum. No eYFP fluorescence could be detected
in the hypothalamus of Ins1Cre/+;Rosa26-eYFP mice, as
shown at two different bregma levels (ESM Fig. 1a, b); sec-
tions of the hypothalamus of control Rosa26-eYFP mice are
shown in ESM Fig. 1c, d. As an alternative means of detecting
c
b d
a e
f
eYFP eYFP eYFP
eYFP-IF eYFP-IF eYFP-IF
Fig. 2 Expression of eYFP in
pancreatic islets of
Ins1Cre/+;Rosa26-eYFP mice. (a,
c, e) eYFP fluorescence is
detected in the pancreatic islets
(a) but not in the liver (c) of 12-
week-old Ins1Cre/+;Rosa26-eYFP
mice; it is not detected in the
pancreas of Rosa26-eYFP mice
(e). (b, d, f) Indirect
immunofluorescence detection of
eYFP (eYFP-IF, red) on tissue
sections corresponding to a, c and
e, respectively. Scale bars, 50 μm
(a–f)
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recombination in the brain, we evaluated expression of eYFP
by immunohistochemistry. No signal could be detected in any
hypothalamic areas of Ins1Cre/+;Rosa26-eYFPmice, as shown
in Fig. 5a–d. Immunohistochemical detection of eYFP in the
beta cells from Ins1Cre/+;Rosa26-eYFP mice is shown as a
positive control (Fig. 5e). Similarly, no positive signals could
be detected in the cortex or thalamus of Ins1Cre/+;Rosa26-
eYFP mice (ESM Fig. 2a–d). Thus, these data are in agree-
ment with the PCR data of Fig. 1c that show absence of
recombination event in the brain of adult Ins1Cre/+;Rosa26-
eYFP mice.
To determine whether introduction of the Cre gene in
the Ins1 locus would cause any deregulation of glucose
homeostasis or impact mouse growth, we generated
cohorts of male and female C57Bl/6J heterozygous
Ins1Cre and littermate controls and followed them for
24 weeks. No difference in body weight gain could be
observed between the control and Ins1Cre mice of either
sex (Fig. 6a). Random fed glycaemia levels were also
identical (Fig. 6b), as was glucose tolerance assessed in
heterozygous 12 week old male and female mice
(Fig. 6c, d).
Finally, to determine whether recombination could be in-
duced in the beta cells of adult Ins1CreERT2/+;Rosa26-
tdTomato mice, we tested several tamoxifen injection proto-
cols. The data of Fig. 7 show that four injections of tamoxifen
(2 mg in corn oil) over a 2 week period in 10 week old mice
induced recombination in approximately 60–70% of beta
cells. No expression of tdTomato could be observed in islets
from corn oil-treated Ins1CreERT2/+;Rosa26-tdTomato mice.
Discussion
Here we describe the generation of two newmouse models for
efficient and selective induction of lox-dependent recombina-
tion in pancreatic beta cells. The Ins1Cre mice induce complete
recombination by the time of birth in all beta cells, whereas the
Ins1CreERT2 mice can be used for tamoxifen-dependent gene
recombination in adult mice.
Several Cre transgenic mice have already been established
for beta cell-specific gene recombination. The present models
use a knock-in strategy to express Cre from the endogenous
Ins1 locus. This locus is known to have a more restricted beta
cell expression than the Ins2 locus, which displays transient
expression in the hypothalamus and other brain structures
[24]. The use of the Ins2 promoter to drive Cre expression
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Fig. 3 Expression of eYFP is restricted to beta cells of Ins1Cre/+;Rosa26-
eYFP mice. eYFP expression in Ins1Cre/+;Rosa26-eYFP mouse islets co-
stained for insulin (a), glucagon (b), pancreatic polypeptide (PP) (c) and
somatostatin (d). Scale bars, 20 μm (a–d)
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MergetdTomato
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Fig. 4 Expression of eYFP in
beta cells of neonatal
Ins1Cre/+;Rosa26-tdTomato mice.
(a) Expression of tdTomato (red)
and co-staining for insulin (green)
in the islet of 1-day-old
Ins1Cre/+;Rosa26-eYFP mice. (b)
Expression of tdTomato (red) and
co-staining for glucagon (green).
Scale bars, 20 μm (a, b)
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led to mouse models with compound genetic recombination in
the islets and brain, leading to complicated interpretation of
the phenotype of mice used [16]. Ins2 knock-in mouse lines
have also been generated [25], but are similarly expected to
recapitulate endogenous expression and result in ectopic
expression in brain. On the other hand, two recent studies
have reported transgenic models expressing Cre or CreER
driven by Ins1 promoter sequences or by an Ins1 locus bacte-
rial artificial chromosome [16, 26]. In keeping with our model,
these mice lack Cre expression in the brain [16, 26]. Our
a
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e
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ArcArc
Fig. 5 No expression of eYFP in the hypothalamus of Ins1Cre/+;Rosa26-
eYFPmice as assessed by immunohistochemistry. Immunohistochemical
detection of eYFP in the hypothalamus of Ins1Cre/+;Rosa26-eYFP and
control Rosa26-eYFP mice at bregma −0.82 (a, c) and −1.70 (b, d). (e)
eYFP immunohistochemical detection in the pancreas from
Ins1Cre/+;Rosa26-eYFP mice. Scale bars, 100 μm. Arc, arcuate
hypothalamic nucleus; LH, lateral hypothalamic area; 3 V, third
ventricle
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Fig. 6 Normal body weight gain,
glycaemic levels and glucose
tolerance in heterozygous Ins1Cre
mice. (a) Body weight of male
(white squares) and female (white
triangles) Ins1Cre mice and their
control littermates (males, black
squares; females, black triangles).
(b) Fed glycaemic levels in 12-
week-old male and female Ins1Cre
mice and their control littermates.
(c, d) Glucose tolerance tests in
12-week-old male (c) and female
(d) Ins1Cre mice and their control
littermates (white symbols,
Ins1Cre mice; black symbols,
control littermates). White bars,
Ins1Cre mice; black bars, control
littermates. Data are mean±SEM;
n=9–13
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model provides further advantages in thatCre is inserted in the
native Ins1 locus and is thus theoretically controlled by all
known and unknown native cis-regulatory sequences, provid-
ing greater ability to recapitulate the endogenous Ins1 expres-
sion pattern. We have indeed verified that recombination is
efficiently induced in pancreatic islet beta cells at birth, where-
as no recombination could be observed in the brain. Further-
more, we report an inducible Ins1CreERT2 mouse line that is
capable of recombination in 60–70% of the beta cells. Impor-
tantly, there was no leakiness of CreERT2 expression as
judged by the absence of tdTomato expression in non-treated
or vehicle-treated mice.
An important aspect of the Ins1Cre mouse model is that its
glucose homeostasis and body weight control are indistin-
guishable from those of control littermates. It has been report-
ed that one of the rat insulin promoter (RIP)-driven Cre mouse
lines [11] has a defect in glucose homeostasis [27], casting
some doubt on the results of reports showing an impact of beta
cell gene deletion using this recombinase line. We have not
tested body weight and glucose homeostasis in cohorts of
Ins1CreERT2 mice. However, because both the Ins1Cre and
Ins1 CreERT2 mice were generated by the same knock-in strat-
egy we anticipate similar effects. In the different transgenic
mouse lines, such as RIP-Cre, functional differences may
result from insertional mutagenesis caused by the random
insertion of the transgene, usually as large concatemers. This
can potentially lead to unwanted effects such as the formation
of loss-of-function alleles, abnormalities in the activity of
nearby genes, and unexpected expression pattern and strength
of the transgene. The knock-in approach used here results in a
well-defined targeted modification that is therefore more pre-
cise and less prone to induction of artefacts. Another theoret-
ical consideration is that the Ins2 promoter is stronger than
Ins1 [28] and could thus result in higher concentrations of Cre
that are potentially deleterious. Importantly, our knock-
in approach does not affect glucose homeostasis despite
suppressing one Ins1 allele, which is also in agreement
with previous studies reporting perfect glycaemic
control in mice with deletion of single alleles of the
Ins1 or Ins2 locus [29].
In summary, we have generated two new Cre deleter mice
that can be used for beta cell-specific constitutive (Ins1Cre) or
inducible (Ins1CreERT2) deletion of genes. The constitutive
deleter mice induce deletion in nearly all beta cells from the
immediate postnatal period to adulthood and they display
normal control of body weight and glycaemia. The inducible
deleter mice will be useful to test the impact of gene deletion
in adult mice or at a defined time during development, al-
though deletion does not occur in all beta cells. These two
mouse strains are therefore very valuable new tools for beta
cell research.
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Fig. 7 Tamoxifen-induced
expression of tdTomato in beta
cells of Ins1CreERT2/+;Rosa26-
tdTomato mice. (a–c) Ten-week-
old Ins1CreERT2/+;Rosa26-
tdTomatomice were injected with
2 mg tamoxifen four times over a
2 week period. Expression of
insulin (green) (a) and tdTomato
(red) (b) was then assessed; (c)
merged images. (d–f) Same as (a–
c) except that mice were injected
with vehicle (corn oil). Scale bars,
50 μm
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